U.S. Markets closed

ImmunoCellular Therapeutics, Ltd. (IMUC)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.35+0.02 (+7.16%)
At close: 4:00PM EDT
People also watch

ImmunoCellular Therapeutics, Ltd.

23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States

Full Time Employees7

Key Executives

Mr. Gary S. Titus CPAChairman and Corp. Sec.72.25kN/A57
Dr. Anthony J. Gringeri Ph.D.Chief Exec. Officer, Pres and Director368.99kN/A64
Dr. John S. Yu M.D., Ph.D.Founder & DirectorN/AN/A53
Mr. David E. Fractor CPAChief Financial Officer202.5kN/A57
Dr. Steven J. Swanson M.D., Ph.D.Sr. VP of Research313.57kN/A61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Corporate Governance

ImmunoCellular Therapeutics, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.